This site is intended for Healthcare Professionals only.

Britain expands access to Pfizer’s oral antiviral Covid-19 treatment through trial


Share post:

Britain will expand access to Pfizer’s oral antiviral Covid-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population, health secretary Sajid Javid said on Tuesday (April 12).

Paxlovid, a combination of Pfizer’s new pill with an older antiviral ritonavir, was made available to thousands of people with compromised immune systems in the UK in February.

Now the drug is being added to the Oxford University-led PANORAMIC national study in England, which is making antivirals available to a wide number of patients while collecting data on how the drugs should best be used in a vaccinated adult population.

Community pharmacy teams have been encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients.

Paxlovid was shown to reduce the relative risk of death or hospitalisation by nearly 90 per cent in clinical trials of high risk individuals given the treatment for five days. Currently it is advised to be taken during the early stages of Covid, though last month was added to another trial for hospitalised patients.

“As we learn to live with Covid, the UK continues to lead the way in using cutting-edge treatments which have already saved the lives of many of the country’s most vulnerable patients,” Javid said in a statement.

He added: “The addition of Paxlovid to the ground-breaking PANORAMIC study is an important milestone and will help us understand who benefits most from these treatments.

“If you’re aged 50 and over or have an underlying health condition and test positive for Covid, I urge you to participate in this study by signing up as soon as you can.”

The PANORAMIC study is open to adults over age 50, or those aged between 18 and 49 who have underlying health conditions that may put them at higher risk for severe Covid.

Paxlovid is the second antiviral to be added to the trial after molnupiravir, a pill made by Merck & Co and Ridgeback Biotherapeutics that did not perform as well in its pivotal clinical trial.

The Department of Health and Social Care said that 20,000 people had joined the Panoramic study since patient recruitment started in December 2021 — to generate data on molnupiravir, with a further 17,500 people to be enrolled to access Paxlovid.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

#SaveOurPharmacies: NPA distributes fair funding campaign posters, stickers

The National Pharmacy Association (NPA) is distributing new campaign materials to pharmacies across England this week to empower...

Lake District pharmacy grapples with medicine shortages amidst growing crisis

79% of pharmacists fear for patient health according to Community Pharmacy England report A Lake District pharmacy is grappling...

Common antibiotic for whooping cough treatment ‘completely out of stock’ – Dr. Leyla Hannbeck

Whooping cough caused five infant deaths in the first quarter of 2024, according to UKHSA Pharmacists in the UK...

Labour with Nuffield Health to aid thousands of NHS staff with joint pain return to work

Nurses accounted for 52,000 of sick days, doctors for 3,500, both up since 2019 as per the Labour...